Among these, topoisomerase inhibitors, CDK inhibitors, and HDAC inhibitors were top hits of MOAs, indicating that drugs targeting these molecules may inhibit transcriptional cancer stemness of HCC (Figure 7C). Here, HDAC9 is linked to hepatocellular carcinoma.